INVO Fertility, Inc.
IVF Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
What INVO Fertility, Inc. does
No business description yet.
- Legal name
- INVO Fertility, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Jun 2, 2026
- Accession Β· CIK
- 0001493152-26-026775
0001417926
Revenue and margins
INVO Fertility, Inc. had $6.8M of revenue in fiscal 2025, up 4.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$7.1M in fiscal 2025, β103.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
INVO Fertility, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 4,584.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably INVO Fertility, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.7M | $0.1M | $0.2M | $0.6M | $2.1M |
| Debt incl. finance leases | β | β | β | $7.5M | $0.9M |
| Debt / equity | β | β | β | 0.6x | 0.1x |
| Interest coverage | β4.1x | β178.9x | β7.3x | β6.3x | β5.6x |
| Current ratio | 5.4x | 0.2x | 0.2x | 0.1x | 0.3x |
| Quick ratio | 5.1x | 0.1x | 0.1x | 0.1x | 0.2x |
| Total assets | $10.0M | $3.7M | $18.5M | $46.1M | $20.2M |
| Total liabilities | $2.7M | $4.7M | $17.6M | $26.0M | $13.0M |
| Shareholders' equity | $7.3M | β$1.0M | $0.9M | $12.6M | $7.2M |
| Net debt (β = net cash) | β | β | β | $6.8M | β$1.2M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 3 / 8 | 7 / 8 | 4 / 8 | 5 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 5 / 9 |
| Accruals ratio | β629.1% | β188.5% | β464.3% | β275.0% | β56.1% | β6.0% | β62.6% | β29.5% | β19.5% | β49.2% |
| Altman Z'' | β358.54 | β365.79 | β138.07 | β50.62 | β6.88 | β9.96 | β68.02 | β14.98 | β7.59 | β19.01 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.1M | $0.3M | $0.5M | $1.5M | $1.0M | $4.2M | $0.8M | $3.0M | $6.5M | $6.8M |
| Gross profit | $0.0M | $0.2M | $0.4M | $1.3M | $0.9M | $4.0M | $0.5M | $1.0M | $2.8M | $6.8M |
| Research and development | β | β | β | $0.0M | $0.4M | $0.2M | $0.5M | $0.2M | $0.0M | β |
| Operating income | β$2.1M | β$0.6M | β$2.6M | β$1.8M | β$5.5M | β$5.2M | β$10.6M | β$6.8M | β$6.6M | β$7.2M |
| Interest expense | $0.0M | $0.0M | $0.4M | $0.4M | $2.8M | $1.3M | $0.1M | $0.9M | $1.1M | $1.3M |
| Pretax income | β$2.1M | β$0.7M | β$3.1M | β$2.2M | β$8.3M | β$6.7M | β$10.9M | β$8.0M | β$7.6M | β$5.5M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | β$0.2M |
| Net income | β$2.1M | β$0.7M | β$3.1M | β$2.2M | β$8.3M | β$6.7M | β$10.9M | β$8.0M | β$9.3M | β$23.3M |
| Net income to common | β$2.1M | β$0.7M | β$3.1M | β$2.2M | β$8.3M | β | β | β$8.0M | β$9.5M | β$25.1M |
| Diluted EPS | β$0.02 | $0.00 | β$0.02 | β$0.45 | β$1.52 | β$0.63 | β$17.97 | β$67.37 | β$3,782.65 | β$214.64 |
| Diluted shares | 0.14B | 0.14B | 0.15B | 0.00B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$0.3M | β$0.2M | β$0.7M | $1.4M | β$4.8M | β$6.0M | β$6.6M | β$4.8M | β$3.0M | β$7.0M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.4M | $0.0M | $0.4M | $0.2M | $0.0M |
| Free cash flow | β$0.3M | β$0.2M | β$0.7M | $1.3M | β$4.8M | β$6.4M | β$6.6M | β$5.2M | β$3.2M | β$7.1M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.2M | $0.9M | $0.7M |
| Stock-based compensation | β | β | $0.0M | $0.1M | $1.1M | $1.5M | $1.6M | β | β | $0.2M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.2M | $0.0M | $0.2M | $1.2M | $10.1M | $5.7M | $0.1M | $0.2M | $0.6M | $2.1M |
| Total debt | β | β | β | β | β | β | β | β | $7.5M | $0.9M |
| Current assets | $0.3M | $0.2M | $0.7M | $1.5M | $10.5M | $6.3M | $0.6M | $1.3M | $1.3M | $2.8M |
| Current liabilities | $4.8M | $5.1M | $3.5M | $1.5M | $2.3M | $1.2M | $3.3M | $8.0M | $17.9M | $10.3M |
| Inventory | $0.1M | $0.1M | $0.0M | $0.1M | $0.3M | $0.3M | $0.3M | $0.3M | $0.2M | $0.2M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.5M | $0.4M | $0.8M | $0.5M | $0.4M |
| Goodwill | β | β | β | β | β | β | β | $5.9M | $5.9M | $5.9M |
| Intangible assets | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | β | $4.1M | $3.3M | $1.3M |
| Total assets | $0.3M | $0.3M | $0.8M | $1.8M | $10.9M | $10.0M | $3.7M | $18.5M | $46.1M | $20.2M |
| Total liabilities | $4.9M | $5.3M | $3.5M | $5.5M | $5.2M | $2.7M | $4.7M | $17.6M | $26.0M | $13.0M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β | β | β |
| Shareholders' equity | β$4.6M | β$5.0M | β$2.7M | β$3.7M | $5.7M | $7.3M | β$1.0M | $0.9M | $12.6M | $7.2M |
| Margins | ||||||||||
| Gross margin | 70.3% | 81.6% | 81.7% | 90.6% | 91.4% | 96.5% | 59.7% | 34.7% | 43.1% | 99.6% |
| Operating margin | β4,146.2% | β227.0% | β532.8% | β120.8% | β531.7% | β125.4% | β1,292.4% | β224.0% | β101.5% | β105.8% |
| EBITDA margin | β4,142.4% | β226.0% | β531.7% | β120.1% | β530.5% | β124.7% | β1,283.0% | β217.4% | β87.4% | β95.9% |
| Net margin | β4,173.5% | β248.9% | β622.2% | β146.4% | β804.7% | β160.0% | β1,324.8% | β266.0% | β141.7% | β340.9% |
| FCF margin | β667.2% | β64.3% | β136.0% | 88.2% | β465.1% | β154.9% | β804.4% | β172.1% | β48.3% | β103.2% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | β | β26.9% | β94.7% |
| Return on capital employed | 47.0% | 13.2% | 96.7% | β607.4% | β63.7% | β59.1% | β2,858.1% | β64.4% | β23.5% | β73.2% |
| Return on equity | β | β | β | β | β822.6% | β102.0% | β344.0% | β | β137.4% | β235.5% |
| Return on assets | β742.2% | β254.1% | β589.5% | β168.5% | β131.0% | β63.6% | β159.0% | β72.3% | β28.7% | β70.4% |
| Return on tangible equity | β | β | β | β | β147.8% | β92.7% | β | β | β277.3% | β125,025.9% |
| Growth | ||||||||||
| Revenue growth | β | 454.2% | 75.3% | 199.4% | β29.9% | 301.1% | β80.2% | 267.4% | 116.2% | 4.7% |
| FCF growth | β | β | β | β | β469.5% | β | β | β | β | β |
| Share count change | β | 1.5% | 4.3% | β96.7% | 13.1% | 93.7% | β94.3% | β80.3% | β97.9% | 4,584.0% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | β | β | β | 0.6x | 0.1x |
| Interest coverage | β152.9x | β30.6x | β6.0x | β4.6x | β1.9x | β4.1x | β178.9x | β7.3x | β6.3x | β5.6x |
| Current ratio | 0.1x | 0.0x | 0.2x | 1.0x | 4.6x | 5.4x | 0.2x | 0.2x | 0.1x | 0.3x |
| Quick ratio | 0.0x | 0.0x | 0.2x | 1.0x | 4.5x | 5.1x | 0.1x | 0.1x | 0.1x | 0.2x |
| Capital allocation | ||||||||||
| Capex / revenue | 30.8% | 0.0% | 3.9% | 4.4% | 4.8% | 10.0% | 1.3% | 14.7% | 2.8% | 0.6% |
| Stock comp / revenue | β | β | 0.0% | 4.7% | 110.0% | 37.1% | 196.6% | β | β | 2.4% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 3.0 | 7.0 | 4.0 | 5.0 | 2.0 | 3.0 | 4.0 | 5.0 |
| Altman Z'' | β358.5 | β365.8 | β138.1 | β50.6 | β6.9 | β10.0 | β68.0 | β15.0 | β7.6 | β19.0 |
| Accruals ratio | β629.1% | β188.5% | β464.3% | β275.0% | β56.1% | β6.0% | β62.6% | β29.5% | β19.5% | β49.2% |
Source: SEC EDGAR XBRL filings (CIK 0001417926). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.